Cytomegalovirus reactivation in patients infected with HIV: The use of polymerase chain reaction in prediction and management

Drugs

Volumn 57, Issue 5, 1999, Pages 735-741

  Bowen, E Frances ^a,b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ST HELIER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS INFECTION; DECISION MAKING; DIAGNOSTIC VALUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESPAN; MORTALITY; POLYMERASE CHAIN REACTION; PREDICTION; PROPHYLAXIS; QUALITY OF LIFE; RETINITIS; REVIEW; RISK; VIRUS REACTIVATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS RETINITIS; DNA, VIRAL; HIV-1; HUMANS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; VIRAL LOAD;

EID: 0032898721     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957050-00006     Document Type: Review

References (24)

1. Zurlo JJ, O'Neill D, Polis MA, et al. Lack of clinical utility of cytomegalovirus blood and urine cultures in patients with HIV infection. Ann Intern Med 1993; 118 (1): 12-7
2. Salmon D, Lacassin F, Harzic M, et al. Predictive value of cytomegalovirus viraemia for the occurrence of CMV organ involvement in AIDS. J Med Virol 1990; 32 (3): 160-3
3. Rasmussen L, Morris S, Zipelo D, et al. Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J Infect Dis 1995; 171 (1): 177-82
4. Spector SA, Merrill R, Wolf D, et al. Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J Clin Microbiol 1992; 30 (9): 2359-65
5. Bek B, Boeckh M, Lepenies J, et al. High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenaemia assay for diagnosis of CMV disease in AIDS patients and follow-up. J Clin Microbiol 1996; 34 (2): 457-9
6. Reynes J, Montes B, Atoni N, et al. Significance of cytomegalovirus (CMV)-pp65 antigenaemia in the diagnosis of CMV disease in human immunodeficiency virus-infected patients. J Med Virol 1996; 49: 195-8
7. Bowen EF, Sabin CA, Wilson P, et al. CMV DNAemia detected by PCR identifies a group of HIV positive patients at high risk of CMV disease. AIDS 1997; 11: 889-93
8. Shinkai M, Bozzette SA, Powderely W, et al. Utility of urine and leukocyte culture and plasma DNA PCR for identification of HIV patients at risk for human CMV disease. J Infect Dis 1997; 175: 502-8
9. Dodt KK, Hoy Jacobsen P, Hoffmann B. Development of CMV disease may be predicted in HIV-infected patients by CMV PCR and the antigenaemia test. AIDS 1997; 11: F21-8
10. Walmsley S, O'Rourke, Mortimer C, et al. Predictive value of CMV antigenaemia and digene capture assay for CMV disease in HIV infected patients. Clin Infect Dis 1998; 27: 573-81
11. Bowen EF, Sabin CA, Wilson P, et al. Cytomegalovirus Retinitis in AIDS patients: influence of CMV load on response to ganciclovir, time to recurrence and survival. AIDS 1996; 10: 1515-20
12. Spector SA, Wong R, Hsia K, et al. Plasma CMV DNA load predicts CMV disease and Survival in AIDS patients. J Clin Invest 1998; 101 (2): 497-502
13. Boivin G, Handfield J, Toma E, et al. Evaluation of the AMPLICOR CMV test with specimens from HIV infected subjects. J Clin Microbiol 1998; 36 (9): 2509-13
14. Rubin RH. Preemptive therapy in immunocompromised hosts [editorial]. N Engl J Med 1999; 324 (15): 1057-9
15. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-8
16. Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991; 324 (15): 1005-11
17. Spector SA, McKinley GF, Lalezari JP, Roche Cooperative Oral Ganciclovir Study Group et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996; 334 (23): 1491-7
18. Feinberg JE, Hurwitz S, Cooper D, et al. A randomised double blind trial of valaciclovir prophylaxis for CMV disease in patients with AIDS. J Infect Dis 1998; 177: 48-56
19. Griffiths PD, Feinberg JE, Sabin C, et al. The effect of valaciclovir on CMV viremia and viruria detected by PCR in patients with advanced HIV disease. J Infect Dis 1998; 177: 57-64
20. Grzywacz M, Bowen EF, Wilson P, et al. Response of asymptomatic viraemia to oral ganciclovir 3g/day or 6g/day. J Med Virol. In press
21. Bowen EF. The natural history of CMV infection in the HIV infected host [PhD thesis]. London: London University, 1997
22. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with HIV infection. N Engl J Med 1998; 338 (13): 853-60
23. Deayton J, Wilson P, Johnson MA, et al. HAART can completely suppress asymptomatic CMV viremia in the absence of specific anti-CMV therapy [abstract]. Interscience Congress Anti-microbial Agents and Chemotherapy (ICAAC) 1998; 1-268
24. Bowen EF, Johnson MA, Wilson P, et al. Cytomegalovirus polymerase chain reaction viraemia in patients receiving maintenance therapy for retinitis. AIDS 1998; 12: 605-11